Bile acid receptor: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
== Structural highlights == | == Structural highlights == | ||
<scene name='54/545859/Cv/ | <scene name='54/545859/Cv/3'>Structure</scene> of human FXR ligand-binding domain (deeppink) complex with non-steroidal agonist, nuclear receptor coactivator 1 peptide (cyan) and sulfate ions (PDB entry [[3ruu]]). <ref>PMID:21890356</ref> | ||
</StructureSection> | </StructureSection> | ||
Revision as of 13:59, 8 January 2019
FunctionBile acid receptor or farnesoid X receptor (FXR) binds bile acids, then translocates to the nucleus, forms a dimer and binds to hormone response elements. This causes up- or down-regulation of certain genes involved in cholesterol metabolism, lipid homeostasis and absorption of fats and vitamins. FXR ligand-binding domain (LBD) binds chenodeoxycholic acid (CDC), lithocholic acid and deoxycholic acid. [1] DiseaseFXR is involved in pathophysiology of inflammatory bowel disease, colorectal cancer and type II diabetes. RelevanceFXR and other bile acid receptors are targets for the treatment of dyslipidemia, diabetes and cardiovascular disease. Structural highlightsof human FXR ligand-binding domain (deeppink) complex with non-steroidal agonist, nuclear receptor coactivator 1 peptide (cyan) and sulfate ions (PDB entry 3ruu). [2]
|
| ||||||||||
3D structures of bile acid receptor3D structures of bile acid receptor
Updated on 08-January-2019
1osh, 3fli, 3l1b – hFXR LBD + non-steroidal agonist - human
1osv – hFXR LBD + CDC derivative + nuclear receptor coactivator 2 peptide
4wvd - hFXR LBD + nuclear receptor corepressor peptide
3bej, 3dct, 3dcu, 3hc5, 3hc6, 3rut, 3ruu, 3rvf – hFXR LBD + non-steroidal agonist + nuclear receptor coactivator 1 peptide
4qe6 – hFXR LBD + CDC + nuclear receptor coactivator 2 peptide
5ick – hFXR LBD + feroline + nuclear receptor coactivator 2 peptide
5q0i – hFXR LBD + PPAR gamma coactivator peptide
5q15, 5wzx – hFXR LBD + coactivator SRC peptide
4qe8 – hFXR LBD + DM175 + nuclear receptor coactivator 2 peptide
5iaw - hFXR LBD + nuclear receptor coactivator 2 peptide + modulator
5q0x, 5q0y, 5q0z, 5q10, 5q11, 5q12, 5q13, 5q14, 5q16, 5q18, 5q19, 5q1a, 5q1b, 5q1c, 5q1d, 5q1e, 5q1f, 5q1g, 5q1h, 5q1i, 5q01, 5q0j, 5q0k, 5q0l, 5q0m, 5q0n, 5q0o, 5q0p, 5q0r, 5q0q, 5q0s, 5q0t, 5q0u, 5q0v, 5q0w, 5q17 - hFXR LBD + coactivator peptide SRC-1 HD3 + ligand
3fxv, 3gd2, 3okh, 3oki, 3olf, 3omk, 3omm, 3oof, 3ook, 3p88, 3p89 – hFXR LBD (mutant) + non-steroidal agonist + nuclear receptor coactivator 1 peptide
1ot7 – hFXR LBD + CDC derivative + RPGR-interacting protein peptide
4oiv – hFXR LBD + antagonist
ReferencesReferences
- ↑ Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):55-67. doi:, 10.1038/nrgastro.2013.151. Epub 2013 Aug 27. PMID:23982684 doi:http://dx.doi.org/10.1038/nrgastro.2013.151
- ↑ Akwabi-Ameyaw A, Caravella JA, Chen L, Creech KL, Deaton DN, Madauss KP, Marr HB, Miller AB, Navas F 3rd, Parks DJ, Spearing PK, Todd D, Williams SP, Wisely GB. Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene. Bioorg Med Chem Lett. 2011 Aug 11. PMID:21890356 doi:10.1016/j.bmcl.2011.08.034